Nimustine

Nimustine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	L01AD06 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name N'-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-(2-chloroethyl)-N-nitrosourea;
CAS Number	42471-28-3 ;
PubChem CID	39214;
ChemSpider	35876 ;
UNII	0S726V972K;
KEGG	D08276 ;
ChEBI	CHEBI:75270 ;
CompTox Dashboard (EPA)	DTXSID0045179 ;
ECHA InfoCard	100.050.744
Chemical and physical data
Formula	C9H13ClN6O2
Molar mass	272.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O;
	InChI InChI=1S/C9H13ClN6O2/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14) ; Key:VFEDRRNHLBGPNN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Nimustine (INN) is a nitrosourea alkylating agent.[1]

It is used to treat malignant brain tumors and has proven to be rather effective.[2][3]

References

"NCI Drug Dictionary". National Cancer Institute. Retrieved 2019-03-17.
CHEBI:75270 - nimustine
Endo T, Inoue T, Sugiyama S, Saito R, Tominaga T (April 2020). "Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review". Operative Neurosurgery (Hagerstown, Md.). 18 (4): 451–459. doi:10.1093/ons/opz172. PMID 31414134.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.